Cargando…
L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy
Lenvatinib is an oral tyrosine kinase inhibitor that acts on multiple receptors involved in angiogenesis. Lenvatinib is a standard agent for the treatment of several types of advanced cancers; however, it frequently causes muscle-related adverse reactions. Our previous study revealed that lenvatinib...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116043/ https://www.ncbi.nlm.nih.gov/pubmed/37089945 http://dx.doi.org/10.3389/fphar.2023.1182788 |